No norovirus vaccine has been approved for use anywhere in the world, but the pipeline is more active than it has ever been. Multiple candidates using different technologies are in clinical trials, with at least one mRNA-based vaccine, one oral tablet vaccine, and several injectable virus-like particle formulations generating promising immune responses in early-phase studies. The virus causes roughly 685 million infections per year globally, and the lack of an approved vaccine or specific antiviral drug means that prevention still rests entirely on hygiene and supportive care when illness strikes.
Why Norovirus Has Been So Hard to Vaccinate Against
Norovirus has frustrated vaccine developers for decades, and the reasons are not just bureaucratic. The virus itself presents a set of biological problems that make vaccine design genuinely difficult. The first and most fundamental obstacle was that scientists could not grow human norovirus in a lab. Unlike many viruses that replicate easily in cell cultures, human norovirus refused to cooperate in standard laboratory conditions. That changed in 2016, when researchers successfully cultivated multiple strains in stem cell-derived human intestinal enteroid cultures, a breakthrough that opened the door to studying how the virus behaves, testing antiviral compounds, and evaluating vaccine candidates far more efficiently than before.1PubMed Central. Replication of human noroviruses in stem cell-derived human enteroids Researchers have since optimized and genetically modified these enteroid cultures to boost viral replication further.2PubMed Central. Insights into human norovirus cultivation in human intestinal enteroids
The second problem is that the virus keeps changing. The GII.4 strains responsible for roughly 80% of norovirus infections worldwide are evolving rapidly, with new epidemic variants emerging every few years. The major surface protein that the immune system targets undergoes antigenic drift, much like influenza viruses do, meaning antibodies that worked against last season’s strain may be less effective against the next one.3PubMed Central. Norovirus GII.4 strain antigenic variation Beyond GII.4, other genotypes such as GII.17 have emerged on multiple continents through recombination events, adding further complexity to any vaccine designed to offer broad protection.4Academia Immunity and Disease. Genetic evolution and vaccine challenges in norovirus genogroup II infection
A third challenge is the nature of immunity itself. Natural infection does not leave you protected for life. Modeling studies estimate that immunity to norovirus gastroenteritis lasts somewhere between four and nine years, depending on the strain and the model used.5PubMed Central. Duration of Immunity to Norovirus Gastroenteritis And even within that window, protection is complicated. A prior GII.4 infection provides some cross-protection against certain other genotypes, but prior infection with some strains actually increases susceptibility to later infection with different ones.6PubMed Central. Homotypic and Heterotypic Protection and Risk of Reinfection Following Natural Norovirus Infection in a Highly Endemic Setting If nature’s own immune response is inconsistent and short-lived, a vaccine needs to do better, and that is a high bar.
Finally, researchers still lack a definitive “correlate of protection,” meaning there is no single measurable immune marker that reliably predicts whether a vaccinated person will resist infection. The best current surrogate is the level of serum antibodies that block the virus from binding to specific sugar molecules on gut cells, known as histo-blood group antigens, or HBGAs. Studies have confirmed that these blocking antibodies correlate with protection from illness and serve as a reasonable stand-in for true neutralization.7PubMed Central. Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody8PubMed Central. Comparison of Microneutralization and Histo-Blood Group Antigen-Blocking Assays for Functional Norovirus Antibody Detection But “correlate” is not the same as “guarantee,” and regulators are cautious about approving vaccines on the basis of a surrogate endpoint alone.
Vaccine Candidates in Clinical Trials
Despite these hurdles, several vaccine candidates have shown they can trigger immune responses in people. They fall into three main technological categories.
Injectable Virus-Like Particle Vaccines
The most clinically advanced approach so far has used virus-like particles, or VLPs. These are protein shells that mimic the outer structure of norovirus but contain no genetic material and cannot cause infection. A bivalent VLP vaccine combining a GI.1 and a GII.4 component, developed by Takeda (formerly LigoCyte and HilleVax), has been through multiple phase 1 and phase 2 trials. In healthy adults, a single dose boosted GI.1 antibody levels by up to 118-fold and GII.4 levels by up to 49-fold in younger adults, with responses peaking around day seven.9PubMed Central. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate–reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults The vaccine was well tolerated, with injection-site pain being the most common side effect and no serious vaccine-related events reported.
A notable finding across several of these VLP trials was that a second dose given weeks later did not meaningfully boost antibody levels beyond what the first dose achieved.10PubMed Central. Rapid Responses to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial Trials in older adults aged 60 and above showed similar immune responses, even among people over 85, with no clinically relevant benefit from adding an immune-boosting adjuvant called MPL to the formulation.11PubMed Central. Bivalent Norovirus VLP Vaccine Candidate in Older Adults: Impact of MPL and a Second Dose in a Randomized, Controlled, Double-Blind Clinical Trial
In a challenge study where vaccinated and unvaccinated volunteers were deliberately exposed to live GII.4 virus, the vaccine did not meet its primary endpoint of preventing infection overall. However, it significantly reduced the severity of illness: no vaccinated participants experienced severe vomiting or diarrhea, compared with about 8% of the placebo group, and a standardized severity score dropped from 7.3 in controls to 4.5 in vaccinated individuals.12PubMed Central. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults The researchers noted that the low overall disease rate in the trial made it difficult to reach statistical significance for the primary outcome. This result captures a frustration common to norovirus vaccine trials: even when a candidate clearly reduces illness severity, demonstrating outright prevention of infection is harder because the virus is so good at getting into cells even when antibodies are present.
Moderna’s mRNA Vaccine
Moderna’s trivalent mRNA candidate, called mRNA-1403, encodes the major capsid protein of three globally common norovirus genotypes: GII.4, GI.3, and GII.3. The vaccine uses the same lipid nanoparticle delivery platform as Moderna’s COVID-19 vaccine. A phase 1/2 dose-ranging trial is underway in healthy adults aged 18 to 80, with interim results reported in late 2024. Phase 1 tested multiple dose levels with either one or two doses, and phase 2 selected three dose levels for further evaluation as a single-dose schedule.13Open Forum Infectious Diseases. 575. Safety and Immunogenicity of mRNA-1403, a Multivalent Norovirus mRNA Vaccine, in Healthy Adults: Interim Results of a Phase 1/2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial The trivalent design is an attempt to address the antigenic diversity problem head-on. If GII.4 alone accounts for the majority of infections but other genotypes still cause substantial illness, covering three at once could offer broader protection than previous bivalent formulations.
Vaxart’s Oral Tablet Vaccine
Taking a fundamentally different route, Vaxart has developed an oral tablet vaccine called VXA-G1.1-NN that uses a non-replicating adenoviral vector to deliver the norovirus GI.1 capsid protein directly to the small intestine. The idea is to trigger mucosal immunity right where the virus attacks, rather than relying solely on systemic antibodies generated by an injection. In a phase 1 trial, the high-dose group met its primary immunological endpoint, with 78% of recipients showing at least a twofold rise in blocking antibody titers after a single tablet.14The Journal of Clinical Investigation. Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial The vaccine also stimulated gut-homing immune cells and fecal IgA, suggesting it was priming immunity at the mucosal level.
A subsequent phase 1b trial in older adults aged 55 to 80 confirmed the vaccine was safe and well tolerated and showed that IgA levels in saliva and nasal lining fluid rose within 28 days and remained above baseline through 210 days, suggesting durable mucosal responses.15PubMed. An oral norovirus vaccine tablet was safe and elicited mucosal immunity in older adults in a phase 1b clinical trial Most recently, a phase 2b challenge study reported that the oral vaccine conferred protection against norovirus GI.1 challenge and reduced viral shedding in both stool and vomit, an important finding because reducing shedding could help limit transmission to others.16PubMed. An oral norovirus vaccine generates mucosal immunity and reduces viral shedding in a phase 2 placebo-controlled challenge study
Who Would Get a Norovirus Vaccine First
Even before a vaccine is approved, researchers have been modeling who would benefit most. Young children, older adults, and people with weakened immune systems face the highest risk of complications from norovirus infection. Healthcare workers and food handlers, meanwhile, are at elevated risk of transmitting the virus to others.17PubMed Central. Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations
A recent modeling study simulated several vaccine formulations and found that a pediatric vaccination program using a GII.4-containing vaccine would be the most effective starting point for reducing overall norovirus attack rates in the population. Adding other genotypes to the vaccine would lower attack rates further, though more incrementally. The study also found that annual vaccination of older adults with a GII.4 vaccine could provide meaningful direct benefits beyond what pediatric vaccination alone would achieve, provided the vaccine confers several months of broad protection against infection.18PubMed. Projecting the population-level impact of norovirus vaccines One nuance the model flagged: in the 10 to 20 years following the rollout of any pediatric vaccine, shifts in which norovirus genotypes circulate should be expected. Though long-term increases in non-vaccine genotypes above baseline were not predicted, public health authorities would need to monitor for unexpected changes in strain circulation patterns.
The Economic Stakes
The cost of norovirus illness helps explain why so many companies and governments are investing in vaccine development. Globally, norovirus causes an estimated $4.2 billion per year in direct healthcare costs and roughly $60 billion in societal costs when lost productivity is included. Children under five account for a disproportionate share of this burden, costing society about $40 billion per year, while all other age groups combined account for the remaining $20 billion.19PubMed Central. Global Economic Burden of Norovirus Gastroenteritis In the United States alone, the estimated annual cost is about $10.6 billion, with sporadic community cases making up over 90% of the total burden and productivity losses accounting for 89%.20PubMed Central. The Clinical and Economic Burden of Norovirus Gastroenteritis in the United States More than half of the U.S. economic burden falls on adults aged 45 and over, a population segment that might seem surprising given how often we associate norovirus with children and cruise ships.
What You Can Do Right Now
With no approved vaccine and no specific antiviral drug, preventing norovirus infection comes down to breaking transmission chains. The virus is stubbornly resilient: it is stable in the environment and resistant to many common disinfectants.21PubMed Central. Antiviral Activity of Olanexidine-Containing Hand Rub against Human Noroviruses It spreads primarily person-to-person and through contaminated food, and it takes only a tiny number of viral particles to start an infection.22PubMed Central. Infection control for norovirus
Hand sanitizer is not enough. Alcohol-based hand rubs, while convenient, are considerably less effective against norovirus than they are against many bacteria and enveloped viruses. Soap and water with thorough friction is the best option. For surfaces, chlorine-based bleach solutions are among the few disinfectants that reliably inactivate the virus. Norovirus can remain intact on common food-contact surfaces for weeks. At refrigerator temperatures, viral capsids barely declined over 70 days in laboratory testing.23PubMed. Tenacity of human norovirus and the surrogates feline calicivirus and murine norovirus during long-term storage on common nonporous food contact surfaces
If you or someone in your household gets sick, the treatment is supportive. The goal is to replace fluids and electrolytes lost through vomiting and diarrhea. Oral rehydration solutions are as effective as intravenous fluids for mild to moderate dehydration, and anti-nausea medication such as ondansetron can help keep oral rehydration on track and reduce the need for hospitalization.24PubMed Central. Paediatrics: how to manage viral gastroenteritis For most people, norovirus illness resolves on its own within one to three days. However, the very young, older adults, and people who are immunocompromised may need closer medical attention. In transplant recipients and other immunocompromised patients, norovirus can cause chronic infection, and treatment is largely limited to supportive care with occasional off-label use of certain medications.25PubMed Central. Clinical Experience of Oral Serum‐Derived Bovine Immunoglobulin in Solid Organ Transplant Recipients Diagnosed With Norovirus Infection
Why Some People Seem Immune
If you know someone who claims they never get stomach bugs, they might not be exaggerating. A person’s susceptibility to norovirus is partly determined by their genetics, specifically by a gene called FUT2. People who carry two copies of a particular loss-of-function mutation in this gene, known as “nonsecretors,” lack certain sugar molecules on the surface of their gut cells that the most common norovirus strains use to gain entry.26PubMed. Ancestral FUT2 genetic adaptation confers resistance to modern norovirus and rotavirus infections In practical terms, nonsecretors are strongly resistant to GII.4 infections. One U.S. study of children found that every single GII.4 case and every asymptomatic GII.4 infection occurred in secretor-positive children.27PubMed Central. Innate Susceptibility to Norovirus Infections Influenced by FUT2 Genotype in a United States Pediatric Population
This does not mean nonsecretors are completely protected from all norovirus strains. A birth cohort study in Ecuador confirmed that while GII.4 exclusively infected secretor-positive children, non-GII.4 genotypes actually infected secretor-negative children at higher rates.28PubMed Central. Norovirus Infection and Disease in an Ecuadorian Birth Cohort: Association of Certain Norovirus Genotypes With Host FUT2 Secretor Status So the protection is strain-specific, not absolute. About 20% of people of European descent are nonsecretors, though the frequency varies across populations. This genetic variation has implications for vaccine trials as well: if a substantial fraction of trial participants are naturally resistant to infection with the challenge strain, it becomes harder to demonstrate that the vaccine itself is working.
Norovirus in Animals and the Transmission Web
Most people think of norovirus as a purely human problem, but evidence has been accumulating that the virus can cross between species. In Thailand, researchers found evidence of norovirus GII.4 infection in both humans and pet dogs from the same households, raising the possibility of bidirectional transmission.29Emerging Infectious Diseases. Human Norovirus Infection in Dogs, Thailand A study in Costa Rica detected GII.4-related strains circulating simultaneously in humans, dogs, and two other animal species, suggesting what the authors described as a zoo-anthropozoonosis, meaning the virus moves from animals to humans and back again.30PubMed Central. Molecular characterization of norovirus and sapovirus detected in animals and humans in Costa Rica: Zoo-anthropozoonotic potential of human norovirus GII.4
This does not mean your dog is likely to give you norovirus. The vast majority of infections are still transmitted person-to-person or through contaminated food and water. But the finding complicates the picture for long-term control. If animals serve as a reservoir, vaccination of humans alone might not completely eliminate certain strains from circulating in the environment.
Food supply chains add another dimension to the problem. Norovirus contamination of produce can occur through irrigation water, and one study demonstrated that human norovirus could persist in reconstituted pesticide solutions, meaning contaminated water used to dilute crop treatments could be an overlooked route by which the virus reaches fresh produce.31PubMed. Persistence of human norovirus in reconstituted pesticides–pesticide application as a possible source of viruses in fresh produce chains These findings underscore that even with a future vaccine, food safety practices and water sanitation will remain essential tools for keeping norovirus in check.
Tracking the Virus With Better Surveillance
One area of quiet progress has been in the technology used to identify and trace norovirus outbreaks. Traditional methods relied on sequencing short fragments of the viral genome, which can identify the broad genotype but often cannot distinguish between closely related strains circulating at the same time. Whole-genome sequencing offers much finer resolution. A surveillance effort in Orange County, California demonstrated that whole-genome analysis could differentiate strains from separate outbreaks that traditional sequencing lumped together, and could detect as few as 15 to 79 single-nucleotide differences between strains from distinct events.32PubMed. Application of whole-genome sequencing for norovirus outbreak tracking and surveillance efforts in Orange County, CA As this technology becomes more widely adopted, health departments will be able to trace outbreaks to their source faster and potentially intervene before they spread. It also lays the groundwork for monitoring how the virus evolves in response to future vaccine pressure, something the modeling studies have flagged as a key concern during the transitional years after any vaccine rollout.